FDA clears monthly Pasatru after Phase 3 data show sharp drop in abnormal bone formation
FDA approves Regeneron’s Pasatru after Phase 3 data showed a 90% reduction in new FOP bone lesions. See what the new therapy means.
Pharma & Biotech